← Drug Development Suite Orientation · Vitalis Therapeutics Inc.

Drug Development Lifecycle Guide

Download Word
Program timeline · status 15 Oct 2026Suite index →
Gate 0
Mar 2022
Go
Stage 1
Nonclinical
Gate 1
Dec 2022
Go
Stage 2
IND & Phase 1
Gate 2
Jun 2023
Go
Gate 3
May 2024
Go
Gate 4
Jun 2026
Go w/ conditions
Stage 4
Phase 3
You are here
Gate 5
Sep 2028
Gate 6
Oct 2029
Launch
Nov 2029

Vitalis Therapeutics Inc. — A plain-English guide to how a drug gets from a selected molecule to a pharmacy shelf, and where program management fits. Written for a reader who does not work in pharmaceutical development. Uses the VitaFlow (VTX-401) program throughout as the worked example.

6–10 yr
Typical duration
7%
Reach approval from Phase 1
3
Clinical phases
4
Agency meetings that matter
Contents
  1. The Shape of the Whole Thing
  2. Before a Human Is Dosed
  3. The IND — Permission to Begin
  4. The Three Clinical Phases
  5. Talking to the Agency
  6. Filing and Review
  7. Who Does What
  8. Where Program Management Adds Value
  9. Vocabulary
  10. How to Read the Rest of This Suite

1. The Shape of the Whole Thing

A drug takes roughly six to ten years to get from a selected molecule to a pharmacy shelf, and most attempts fail. Understanding why it takes that long, and where the failures happen, is the foundation everything else rests on.

The sequence is fixed and cannot be reordered:

StageQuestion it answersTypical duration
DiscoveryIs there a molecule worth testing?2–5 years
NonclinicalIs it safe enough to give a human?1–2 years
INDWill the agency let us start?30 days
Phase 1Is it safe in people, and what does the body do to it?6–12 months
Phase 2Does it work, and at what dose?1–2 years
Phase 3Does it work at scale, safely, against a control?2–4 years
NDA reviewWill the agency approve the label we asked for?10–12 months
LaunchCan we supply it and will anyone pay for it?ongoing
The one number that explains the industry. Of drugs that enter Phase 1, roughly 7% reach approval. The attrition is not evenly spread — Phase 2 is where most programs die, because Phase 2 is the first honest test of whether the drug works.

Every structural feature of pharmaceutical program management follows from that number. Staged funding exists because most programs should stop. Gates exist because the information arrives in discrete lumps. Governance is designed around termination being the normal outcome, not the failure case.

2. Before a Human Is Dosed

Nonclinical — the safety package

Before any person receives the drug, the sponsor must have evidence that a reasonable starting dose is unlikely to hurt them. That evidence comes from animal studies conducted under Good Laboratory Practice (GLP): toxicology at escalating doses, safety pharmacology on the cardiovascular, respiratory and nervous systems, and pharmacokinetics establishing how the body absorbs, distributes, metabolizes and eliminates the compound.

This work is unglamorous, slow, and cannot be compressed. It is also where a program discovers cheaply that a molecule is not viable.

CMC — can you actually make it?

Chemistry, Manufacturing and Controls is the discipline most often underestimated by people new to the field, and the one that most often moves a filing date.

CMC has to answer: what is the synthetic route, is it reproducible, what are the impurities and are they acceptable, how is the finished product formulated, what analytical methods prove identity and purity, and how long is it stable. Every one of those answers must hold not just in a research laboratory but at commercial scale in a validated facility.

Why CMC surprises people. The clinical question — does the drug work — is intellectually interesting and gets the attention. The manufacturing question — can we make this batch after batch to specification — is treated as routine engineering. It is not. In this program, I-02 was an analytical method transfer that failed first-pass acceptance, cost $1,850,000, and appeared on no risk register beforehand.

3. The IND — Permission to Begin

The Investigational New Drug application is what converts a laboratory compound into something legally administrable to humans in the United States. It packages the nonclinical safety data, the CMC information, and the proposed first clinical protocol.

The mechanic worth knowing: an IND is not approved. It is submitted, and if the agency does not object within 30 days, the sponsor may proceed. Silence is permission. If the agency has concerns it issues a clinical hold, and dosing cannot begin until the hold is resolved.

In this program the IND cleared its 30-day review in June 2023. Note how the suite treats it: Gate 2 is a submission gate and releases no funding tranche. The agency's review clock is a regulatory event, not a governance decision, and building a funding gate around it would hand the release schedule to an external timetable.

4. The Three Clinical Phases

Each phase answers a different question. Running them out of order, or asking one to answer another's question, is the most common conceptual error.

Phase 1 — safety and pharmacokinetics

Small, usually healthy volunteers, usually not looking for efficacy at all. Two designs run in sequence: single ascending dose, then multiple ascending dose. The questions are what the body does to the drug, what the drug does to the body at increasing exposures, and where tolerability starts to degrade.

In this program: 64 volunteers over 12 weeks.

Phase 2 — does it work, and at what dose

Patients with the actual condition, several dose arms, a control. This is the first honest test of the hypothesis and it is where most programs end.

The design choice that matters most is dose span. A narrow span is cheaper and answers the selection question. A wider span costs more and also tells you where the ceiling is. This program deliberately carried a wide span — 480 participants over 36 weeks — specifically so that if tolerability degraded at the top dose, it would degrade in Phase 2 where the finding is affordable rather than in Phase 3 where it is not.

Phase 3 — confirmation at scale

Large, long, and designed to support a label rather than to answer a scientific question. The endpoints are agreed with the agency in advance. The population matches the intended indication. The comparison is usually against placebo, sometimes against standard of care.

In this program: 2,480 participants across two pivotal trials of 68 weeks, plus a nested cardiovascular sub-study. That is $109,100,000, 50% of the entire program budget.

Why "adequate and well-controlled" usually means two trials. A single trial can support approval and often does. Two independently randomized trials showing the same result are substantially harder to attribute to chance or to one site network's characteristics. Where a program's commercial claim will be contested, replication is worth its cost.

5. Talking to the Agency

FDA interactions are formal, scheduled, minuted, and far more consequential than their frequency suggests. Four matter across a development program.

MeetingWhenWhat it settles
Pre-INDBefore the IND is filedWhether the nonclinical package is sufficient and the first-in-human design is acceptable
End-of-Phase-1After Phase 1 reads outPhase 2 design and dose selection
End-of-Phase-2After Phase 2 reads outThe pivotal design, the endpoints, and the safety expectations. The most consequential meeting in a development program.
Pre-NDABefore submissionContent and format of the filing, integrated summaries, labeling strategy
Why End-of-Phase-2 outranks most of the gates. Three things get settled there and none of them can be changed afterward without going back: what the trial has to prove, how it will be measured, and what safety evidence the agency expects alongside it.

In this program that meeting on 19 May 2026 fixed the co-primary endpoints and produced the cardiovascular safety expectation that became CR-02 — a $7,200,000 scope addition and six months of schedule. Gate 4 was deliberately scheduled after it, so the $125,800,000 Phase 3 authorization was taken with the agency's position known rather than assumed.

6. Filing and Review

What an NDA is

A New Drug Application is the complete evidentiary case for a specific label. It is organized in modules covering administrative information, summaries, quality (CMC), nonclinical study reports, and clinical study reports. It typically runs to hundreds of thousands of pages.

Two filing routes matter:

The review clock

Submission does not start the clock. The agency has 60 days to decide whether the application is complete enough to review — filing acceptance. From that point a standard review runs about 10 months to the PDUFA action date, the date by which the agency commits to respond. Priority review compresses this to roughly 6 months.

During review the agency issues information requests, which arrive with short deadlines and consume the sponsor team continuously. Labeling is negotiated in the final months.

Pre-approval inspection

Before approval, the agency inspects the manufacturing site. Observations are issued on Form 483. Unresolved significant observations delay approval regardless of how good the clinical data are.

A filing date is a manufacturing date as much as a clinical one. Registration batches must be made, placed on stability, and process validation completed before submission. Teams new to development consistently plan manufacturing readiness as though it runs parallel to clinical read-out. In practice it gates the submission independently.

7. Who Does What

A development program is a coalition of specialist functions, most of which do not report to the program manager.

FunctionOwns
Clinical DevelopmentProtocol design, medical monitoring, interpretation
Clinical OperationsTrial execution, sites, monitoring, the CRO relationship
BiostatisticsAnalysis plan, randomization, sample size, the read-out
Data ManagementDatabase design, data cleaning, query resolution, lock
Nonclinical / ToxicologyAnimal safety, IND-enabling package
CMC / Technical OperationsMaking the drug, at scale, to specification
Quality AssuranceGxP compliance, audits, inspection readiness
PharmacovigilanceAdverse event collection, expedited reporting, signal detection
Regulatory AffairsAgency strategy, submissions, the relationship
Market AccessPayer evidence, pricing, reimbursement
Program ManagementThe seams between all of the above

External partners

Most of the money leaves the building. A CRO runs the trials, a CMO manufactures, a central laboratory processes samples. In this program, internal salary is 17% of the budget and the other 83% is external.

The management consequence. Most of a development budget is controlled through contracts, not through line management. A program that runs its own headcount tightly and its vendor commitments loosely has optimized the small number.

8. Where Program Management Actually Adds Value

A sponsor program manager does not design the trial, write the protocol, run the statistics or make the drug. Every one of those belongs to a specialist function. So what is the job?

ContributionWhat it looks like
Owning the seamsNobody else is accountable for the handoff between CMC readiness and the filing date, or between database lock and topline analysis. That is where programs lose time.
Sequencing decisions against informationScheduling a gate after the agency meeting rather than before it. Knowing that a decision taken six weeks early is taken blind.
Making commitment staged rather than totalTranche release, staged vendor work packages, and the discipline not to contract scope a future gate may decline to fund.
Surfacing weak positions in writingA condition with a fixed verification method, an abstention with its reason recorded, a risk named before it becomes an issue.
Translating between functionsClinical, CMC, regulatory and commercial all have valid and competing timelines. Someone has to hold all four at once.
Protecting the decision from the desireEvery program wants to proceed. The governance system exists so that wanting to is not sufficient.
The single most useful thing a development PM knows is which choices are fixed, which are schedule-critical, and which are cost-critical.

Under enrolment pressure the tempting moves are all in the fixed column: relax an exclusion, shorten the treatment period, drop an endpoint. Each would help the schedule and each would cost the filing. The moves genuinely available are more sites, faster activation, or a decision to spend more. Knowing which is which before the pressure arrives is most of the job.

9. Vocabulary

TermMeaning
INDInvestigational New Drug application — permission to dose humans
NDA / BLANew Drug Application (small molecules) / Biologics License Application
505(b)(1) / 505(b)(2)Full application / application relying partly on prior agency findings
PDUFA dateThe agency's committed action date on a filing
GLP / GCP / cGMPGood Laboratory / Clinical / current Good Manufacturing Practice
GxPCollective term for the above
CRO / CMOContract Research Organization / Contract Manufacturing Organization
CMCChemistry, Manufacturing and Controls
DMC / DSMBData Monitoring Committee — independent unblinded safety oversight
IRB / ECInstitutional Review Board / Ethics Committee — site-level human subject protection
SAESerious Adverse Event — carries expedited reporting obligations
EstimandThe precise quantity a trial is estimating, including how dropouts are treated
Screen failureA consented participant who does not meet eligibility and is not randomized
Database lockThe point at which trial data are frozen for analysis
ToplineFirst unblinded summary of whether the primary endpoint was met
Form 483Written observations issued at the close of an FDA inspection
REMSRisk Evaluation and Mitigation Strategy — required risk controls on a label
Gross-to-netThe gap between list price and what the manufacturer actually receives
PoS / LOAProbability of Success / Likelihood of Approval

10. How to Read the Rest of This Suite

With the lifecycle in hand, the artifacts fall into a natural reading order.

  1. Program Story — the narrative arc, start here.
  2. Product Definition — what the program is trying to prove, and what it conceded.
  3. Program Charter — what was authorized, and what was deliberately not.
  4. Development Committee Charter and Gate Decision Framework — who decides and against what.
  5. Phase 3 Protocol Summary — the clinical work, from a program manager's angle.
  6. Program Budget — where the money goes and how it is released.
  7. RAID Log, Conditions and Contingency — what is uncertain and what it cost.
  8. Post-Launch Review — what actually happened, against all of the above.
  9. Sources & Benchmarks — how to check the numbers.
If you read only two: the Program Story for how a development program actually unfolds, and the Post-Launch Review for what the governance record turned out to be worth. The second is deliberately not a success story.